Vectus Biosystems Limited (ASX:VBS) Releases December 2024 Quarterly Activities Report
Vectus Biosystems Limited (ASX:VBS) releases its December 2024 Quarterly Activities Report, detailing clinical trial progress and a strong financial position.
Category: Healthcare
Opthea Limited (ASX:OPT) Releases Q2 FY25 Activity Report
Opthea Limited (ASX:OPT) releases Q2 FY25 Activity Report, detailing advancements in Phase 3 trials and financial developments including a R&D tax incentive.
Althea Group Holdings (ASX:AGH) Reports Quarterly Results
Althea Group Holdings (ASX:AGH) announces $9.01 million in Q2 receipts, with ongoing governance improvements and operational strides in cannabis.
Superior Resources Limited (ASX:SPQ) Reports Significant Progress in Q4 Activities
Superior Resources Limited (ASX:SPQ) reports notable progress in exploration, including new gold zones and funding for drilling initiatives.
Nova Eye Medical Limited (ASX:EYE) Completes $6.6 Million Placement
Nova Eye Medical Limited (ASX:EYE) secures $6.6 million to expand operations and enhance growth in the ophthalmic technology sector.
Nova Eye Medical Limited (ASX:EYE) Announces Capital Raise to Drive Growth
Nova Eye Medical (ASX:EYE) announces a capital raise to bolster its financial stability and operational growth amid increasing demand in the ophthalmology sector.
Hawthorn Resources Limited (ASX:HAW) Quarterly Activities Report
Hawthorn Resources Limited (ASX:HAW) highlights significant advancements in the Mt Bevan magnetite project and ongoing developments in the Anglo Saxon gold initiatives.
EVE Health Group (ASX:EVE) Announces Strategic Developments
EVE Health Group (ASX:EVE) shares updates on its operational achievements and financial performance, focusing on growth and strategic initiatives.
KNeoMedia Limited (ASX: KNM) Provides Quarterly Update
KNeoMedia Limited (ASX: KNM) outlines key financial developments and contract progress in its quarterly update.
Avecho Biotechnology Limited (ASX: AVE) Reports Q4 Activities
Avecho Biotechnology Limited reports progress in its Phase III CBD clinical trial and significant manufacturing achievements in Q4 2024.